share_log

NLS Pharmaceutics Analyst Ratings

NLS Pharmaceutics Analyst Ratings

NLS 藥學分析師評級
Benzinga Analyst Ratings ·  2022/11/08 22:02
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
11/08/2022 — Maxim Group Downgrades Buy → Hold
09/06/2022 933.24% Laidlaw & Co. → $6 Initiates Coverage On → Buy
03/12/2021 1966.47% Brookline Capital → $12 Initiates Coverage On → Buy
03/03/2021 1277.65% Maxim Group → $8 Initiates Coverage On → Buy
日期 上行/下行 分析公司 目標價格變動 評級變動 之前/當前的評級
2022 年 8 月 11 日 — Maxim 集團 降級 買入 → 持有
09/06/2022 933.24% Laidlaw & Co. → 6 美元 啓動覆蓋範圍開啓 → 購買
2021 年 12 月 3 日 1966.47% 布魯克林資本 → 12 美元 啓動覆蓋範圍開啓 → 購買
03/03/2021 1277.65% Maxim 集團 → 8 美元 啓動覆蓋範圍開啓 → 購買

NLS Pharmaceutics Questions & Answers

NLS 藥學問題與解答

What is the target price for NLS Pharmaceutics (NLSP)?
NLS Pharmaceutics（NLSP）的目標價格是多少？

The latest price target for NLS Pharmaceutics (NASDAQ: NLSP) was reported by Maxim Group on November 8, 2022. The analyst firm set a price target for $0.00 expecting NLSP to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.

Maxim集團於2022年11月8日公佈了NLS製藥公司（納斯達克股票代碼：NLSP）的最新目標股價。該分析公司將目標股價定爲0.00美元，預計NLSP將在12個月內降至12個月內（可能下跌-100.00％）。去年有2家分析公司公佈了評級。

What is the most recent analyst rating for NLS Pharmaceutics (NLSP)?
NLS Pharmacetics（NLSP）的最新分析師評級是多少？

The latest analyst rating for NLS Pharmaceutics (NASDAQ: NLSP) was provided by Maxim Group, and NLS Pharmaceutics downgraded their hold rating.

NLS Pharmacetics（納斯達克股票代碼：NLSP）的最新分析師評級由Maxim集團提供，NLS Pharmacetics下調了持倉評級。

When is the next analyst rating going to be posted or updated for NLS Pharmaceutics (NLSP)?
NLS Pharmacetics（NLSP）的下一次分析師評級何時發佈或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NLS Pharmaceutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NLS Pharmaceutics was filed on November 8, 2022 so you should expect the next rating to be made available sometime around November 8, 2023.

分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與NLS Pharmacetics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。NLS Pharmacetics的最新評級是在2022年11月8日公佈的，因此您應該預計下一個評級將在2023年11月8日左右公佈。

Is the Analyst Rating NLS Pharmaceutics (NLSP) correct?
NLS Pharmacetics（NLSP）的分析師評級是否正確？

While ratings are subjective and will change, the latest NLS Pharmaceutics (NLSP) rating was a downgraded with a price target of $0.00 to $0.00. The current price NLS Pharmaceutics (NLSP) is trading at is $0.58, which is out of the analyst's predicted range.

儘管評級是主觀的，並且會發生變化，但最新的NLS Pharmacetics（NLSP）評級已下調，目標股價爲0.00美元至0.00美元。NLS Pharmacetics（NLSP）目前的交易價格爲0.58美元，超出了分析師的預期區間。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論